

Supplementary Table 2: Results for 12 month treatment duration scenarios

Summary of the economic analysis results using 12 month treatment duration				
	Usual care	STS HM	STS HH	TM
Total costs				
Including Home-HF ¹²	£8,562	£9,564	£10,582	£10,326
Excluding Home-HF ¹²	£8,562	£9,708	£10,707	£10,698
Total QALYs				
Including Home-HF ¹²	2.4137	2.3536	2.5589	2.5576
Excluding Home-HF ¹²	2.4137	2.4044	2.6005	2.7065
ICERs				
Including Home-HF ¹²		Dominated	£205,812 ^a	£12,257
Excluding Home-HF ¹²		Dominated	Extendedly dominated	£7,296 ^a
Probability of cost-effectiveness				
Including Home-HF ¹²	7%	19%	34%	40%
Excluding Home-HF ¹²	1%	7%	19%	73%

STS HM, structured telephone support via human to machine interface; STS HH, structured telephone support via human to human contact; TM, telemonitoring; UC, usual care; QALYs, quality adjusted life years; NB, net benefit; ICERs, incremental cost-effectiveness ratios

^a last strategy in the cost-effectiveness frontier

Cost-effectiveness of TM during office hours for 12 months vs. TM during office hours for 6 months

	TM during office hours for 6 months		TM during office hours for 12 months		ICER (TM for 12 months vs. TM for 6 months)
	Costs	QALYs	Costs	QALYs	
Including Home-HF ¹²	£9,437	2.4944	£10,326	2.5576	£14,066/QALY
Excluding Home-HF ¹²	£9,665	2.5847	£10,698	2.7065	£8,481/QALY

TM, telemonitoring; UC, usual care; QALYs, quality adjusted life years; ICERs, incremental cost-effectiveness ratios

Cost-effectiveness of TM during office hours for 12 months vs. TM during office hours for 6 months in situations with a limited number of TM devices

	<i>N</i> patients on TM during office hours for 12 months and <i>N</i> patients on usual care ^a		2* <i>N</i> patients on TM during office hours for 6 months		ICER (TM for 12 months vs. TM for 6 months)
	Costs	QALYs	Costs	QALYs	
Including Home-HF ¹²	£18,888	4.9713	£18,874	4.9888	Dominant
Excluding Home-HF ¹²	£19,260	5.1202	£19,330	5.1694	£1,423/QALY

TM, telemonitoring; UC, usual care; QALYs, quality adjusted life years; ICERs, incremental cost-effectiveness ratios